• Home
  • Contact Us!
  • Privacy Policy

Radio Metta

  • Home
  • Business
  • Education
  • Health
  • Home Deco
  • News
  • Real Estate
  • Technology
  • Contact Us!
  • Privacy Policy
Home» Health»Brainstorm Health: Biotech R&D, Tobacco 21, Criminal Opioid Case

Brainstorm Health: Biotech R&D, Tobacco 21, Criminal Opioid Case

Loknath Das 24 Apr 2019 Health Comments Off on Brainstorm Health: Biotech R&D, Tobacco 21, Criminal Opioid Case 10 Views

Image result for Brainstorm Health: Biotech R&D, Tobacco 21, Criminal Opioid CaseBig pharma companies are in an ROI rut. But that doesn’t mean drug developers at large are grappling with a midlife crisis. In fact, the young guns of the industry—upstart biotechs—aren’t doing too shabby, according to a new Iqvia Institute report.

There have been a few notable shifts in drug development culture as legacy, big-name biopharmas struggle to maintain their ROI of old. Leaner, meaner biotechs have climbed the investor hype ladder while attracting buyout offers from the industry titans (see: any of the deals for startup gene therapy and cancer immunotherapy treatments in just the past few years).

“Emerging biopharma companies (EBP) are defined as companies that are estimated to spend less than $200 million annually on R&D and have less than $500 million in revenue,” wrote the study authors. And these companies accounted for “72% of the total [drug] R&D pipeline in 2018, compared with 61% in 2008… Large pharma companies—those with more than $10 billion in annual pharmaceutical sales—have seen their share drop from 31% to 20% over the same period.”

Let’s put an even finer point on the issue: “Emerging biopharma companies were the originator of 38 of the [new active drug compounds] launched in 2018, or 64% of them.”

This isn’t to say the mainstays of the drug industry have nothing to offer anymore—after all, they can douse the up-and-coming biotechs with cash to help them conduct clinical trials and commercialize their products. But their central roles as the original innovators in this admittedly risky space has clearly diminished. And that may foretell even greater shifts in the pharma business landscape.

[“source=fortune”]

21 Biotech Brainstorm Case Criminal Health Opioid R&D tobacco? 2019-04-24
Tags 21 Biotech Brainstorm Case Criminal Health Opioid R&D tobacco?
Facebook Twitter Stumble linkedin Pinterest More

Authors

Posted by : Loknath Das
Previous Article :

UP RERA rejects applications of 36 real estate projects

Next Article :

ITC’s hospitality forays – the less talked about business interest of tobacco/FMCG giant

Related Articles

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022

This Relentless Pandemic Can Tax Your Mental Health. Here’s How to Cope

Loknath Das 11 Apr 2022

Study: Two New Early Signs of Parkinson’s Disease Identified

Loknath Das 05 Apr 2022

Latest Post

News

Your SEO Budget Is Determining Your Success

admin 03 Sep 2022
News

WAN Connection Method – Frame Relay

admin 26 Aug 2022
Education

GESS Proudly Supports and Sponsors UAE Based Team in Global STEM Challenge

Loknath Das 28 Jul 2022
Technology

The Samsung Galaxy Z Flip4 gets FCC certification

Loknath Das 22 Jul 2022
Education

USF faculty, students to present at 2022 American Educational Research Association Annual Meeting

Loknath Das 22 Jul 2022
Technology

“Critical” We Understand Digital Money’s Impact: US Policymaker

Loknath Das 07 Jun 2022
Health

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022
June 2023
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« Sep    
  • Home
  • Contact Us!
  • Privacy Policy
Copyright 2016, All Rights Reserved
Magazine Blog News WordPress Theme